• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

1H NMR-Based Metabolomics Reveals Refined-Huang-Lian-Jie-Du-Decoction (BBG) as a Potential Ischemic Stroke Treatment Drug With Efficacy and a Favorable Therapeutic Window
This study was carried out in accordance with the recommendations of Animal Ethics Committee of China Pharmaceutical University. The protocol was approved by Animal Ethics Committee of China Pharmaceutical University. Author Contributions JW, MY, and LK conceived the experiments and helped to coordinate support and funding. XF performed the research and drafted the manuscript. SL, YL, and DX participated in the experiments. JW analyzed the data and edited the paper. All authors read and approved the final manuscript. Conflict of Interest Statement The authors declare that the research was conducted in the absence of an...
Source: Frontiers in Pharmacology - April 11, 2019 Category: Drugs & Pharmacology Source Type: research

Hypertension Canada ’s 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults
Publication date: Available online 10 March 2017 Source:Canadian Journal of Cardiology Author(s): Alexander A. Leung, Stella S. Daskalopoulou, Kaberi Dasgupta, Kerry McBrien, Sonia Butalia, Kelly B. Zarnke, Kara Nerenberg, Kevin C. Harris, Meranda Nakhla, Lyne Cloutier, Mark Gelfer, Maxime Lamarre-Cliche, Alain Milot, Peter Bolli, Guy Tremblay, Donna McLean, Sheldon W. Tobe, Marcel Ruzicka, Kevin D. Burns, Michel Vallée, G. V. Ramesh Prasad, Steven E. Gryn, Ross D. Feldman, Peter Selby, Andrew Pipe CM, Ernesto L. Schiffrin, Philip A. McFarlane, Paul Oh, Robert A. Hegele, Milan Khara, Thomas W. Wilson, S. Brian Penner, El...
Source: Canadian Journal of Cardiology - March 9, 2017 Category: Cardiology Source Type: research

Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults
Publication date: May 2017 Source:Canadian Journal of Cardiology, Volume 33, Issue 5 Author(s): Alexander A. Leung, Stella S. Daskalopoulou, Kaberi Dasgupta, Kerry McBrien, Sonia Butalia, Kelly B. Zarnke, Kara Nerenberg, Kevin C. Harris, Meranda Nakhla, Lyne Cloutier, Mark Gelfer, Maxime Lamarre-Cliche, Alain Milot, Peter Bolli, Guy Tremblay, Donna McLean, Sheldon W. Tobe, Marcel Ruzicka, Kevin D. Burns, Michel Vallée, G.V. Ramesh Prasad, Steven E. Gryn, Ross D. Feldman, Peter Selby, Andrew Pipe, Ernesto L. Schiffrin, Philip A. McFarlane, Paul Oh, Robert A. Hegele, Milan Khara, Thomas W. Wilson, S. Brian Penner, Ellen Bu...
Source: Canadian Journal of Cardiology - April 25, 2017 Category: Cardiology Source Type: research

Another Chance for Medtronic ’s Renal Denervation Therapy
Medtronic has yet another chance to prove its renal denervation therapy can treat uncontrolled hypertension. The Dublin-based company has received FDA approval to begin a clinical trial to evaluate the Symplicity Spyral renal denervation system with patients on medication for high blood pressure. The ON MED Trial is a 2:1 randomized, sham-controlled study and will randomize up to 340 patients at 55 centers in the U.S., Japan, Europe, Australia and Canada. Patients will be followed out to three years. Primary safety endpoints will include major adverse events at one month and new renal artery stenosis at six months. The pri...
Source: MDDI - November 8, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news